84913-19-9Relevant articles and documents
Conjugated block copolymers via functionalized initiators and click chemistry
Smith, Kendall A.,Pickel, Deanna L.,Yager, Kevin,Kisslinger, Kim,Verduzco, Rafael
, p. 154 - 163 (2014)
Conjugated block copolymers are potentially useful for organic electronic applications and the study of interfacial charge and energy transfer processes; yet few synthetic methods are available to prepare polymers with well-defined conjugated blocks. Here
IMINO SULFANONE INHIBITORS OF ENPP1
-
Paragraph 0262-0263, (2021/11/13)
The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine- based inhibitors of ENPP1 of Formula (I) and methods of their use for treating disease mediated by ENPP1.
IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST
-
Paragraph 0431-0432, (2020/08/22)
Disclosed herein is an imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as a TLR7 agonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as TLR7 agonist.
Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
-
Paragraph 1379, (2015/09/22)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
New adamantane phenylalkylamines with σ-receptor binding affinity and anticancer activity, associated with putative antagonism of neuropathic pain
Riganas, Stefanos,Papanastasiou, Ioannis,Foscolos, George B.,Tsotinis, Andrew,Serin, Guillaume,Mirjolet, Jean-Fran?ois,Dimas, Kostas,Kourafalos, Vassilios N.,Eleutheriades, Andreas,Moutsos, Vassilios I.,Khan, Humaira,Georgakopoulou, Stavroula,Zaniou, Angeliki,Prassa, Margarita,Theodoropoulou, Maria,Mantelas, Athanasios,Pondiki, Stavroula,Vamvakides, Alexandre
, p. 10241 - 10261 (2013/01/16)
The synthesis of the adamantane phenylalkylamines 2a-d, 3a-c, and 4a-e is described. These compounds exhibited significant antiproliferative activity, in vitro, against eight cancer cell lines tested. The σ1, σ2, and sodium channel binding affinities of compounds 2a, 3a, 4a, and 4c-e were investigated. The most interesting analogue, 4a, exhibited significant in vivo anticancer profile on pancreas, prostate, leukemia, and ovarian cancer cell line xenografts together with apoptosis and caspase-3 activation. Inhibition of the cancer cells cycle at the sub-G1 level was also obtained with 4a. Finally, encouraging results were observed with 4a in vivo on mice, suggesting putative antimetastatic and analgesic activities of this compound.
COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
-
, (2012/04/23)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES
-
Page/Page column 50, (2011/11/30)
The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, B, R1, R2, R3, R4a, R5, and Z are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as aurora.
Compounds having beta adrenergic receptor agonist and muscarinic receptor antagonist activity
-
Page/Page column 36-37, (2008/06/13)
This invention provides compounds of formula I: wherein R1, R2, R4, R5, R6, R7, R8a, R8b, W, a, b, c and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Accordingly, such compounds are expected to be useful as therapeutic agents for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
Asymmetric synthesis of lometrexol ((6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid)
Barnett,Wilson,Wendel,Winningham,Deeter
, p. 7038 - 7045 (2007/10/02)
An enantioselective synthesis of lometrexol (1) which utilizes (5R)-2-piperidone 18 as a key intermediate is described. Lipase-catalyzed enantioselective esterification of 1,3-propanediol derivative 5 provided (R)-(+)-6, the absolute configuration of whic
